Brain cancer gene therapy developments: an interim clinical update that outlines early trial progress and broader program context.
Key Takeaways
- Twenty patients completed screening and ten patients were enrolled and treated
- Interim analysis reported no dose-limiting toxicity or treatment-related Grade four or higher adverse events
- Separate program for hepatocellular carcinoma recently received FDA RMAT designation